Abstract
Spinal muscular atrophy (SMA) is caused by mutations that reduce the level of the survival motor neuron protein (SMN) resulting in death of alpha-motor neurons, yet it is unclear why these cells are preferentially affected by a reduction in this ubiquitously-expressed protein. In mouse models of SMA, one of the earliest events detected is defects at the neuromuscular junction (NMJ). Although NMJs are established at a normal frequency, there are structural as well as functional perturbations and a lack of maturation of the primitive synapse. These early defects are followed by loss of the NMJ, denervation of the muscle and onset of muscle atrophy. In this review, we discuss our current understanding of the contribution of NMJ dysfunction in SMA disease pathogenesis, and also provide an overview of therapies currently under preclinical and clinical development for treatment of SMA.
Keywords: Genetic disease, neuromuscular junction, pathogenesis, spinal muscular atrophy.
Current Molecular Medicine
Title:At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Volume: 13 Issue: 7
Author(s): B. B. Goulet, R. Kothary and R. J. Parks
Affiliation:
Keywords: Genetic disease, neuromuscular junction, pathogenesis, spinal muscular atrophy.
Abstract: Spinal muscular atrophy (SMA) is caused by mutations that reduce the level of the survival motor neuron protein (SMN) resulting in death of alpha-motor neurons, yet it is unclear why these cells are preferentially affected by a reduction in this ubiquitously-expressed protein. In mouse models of SMA, one of the earliest events detected is defects at the neuromuscular junction (NMJ). Although NMJs are established at a normal frequency, there are structural as well as functional perturbations and a lack of maturation of the primitive synapse. These early defects are followed by loss of the NMJ, denervation of the muscle and onset of muscle atrophy. In this review, we discuss our current understanding of the contribution of NMJ dysfunction in SMA disease pathogenesis, and also provide an overview of therapies currently under preclinical and clinical development for treatment of SMA.
Export Options
About this article
Cite this article as:
Goulet B. B., Kothary R. and Parks J. R., At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression, Current Molecular Medicine 2013; 13 (7) . https://dx.doi.org/10.2174/15665240113139990044
DOI https://dx.doi.org/10.2174/15665240113139990044 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antithrombotic Therapy
Current Molecular Medicine Is There a Genetic Susceptibility to Bronchopulmonary Dysplasia?
Current Respiratory Medicine Reviews Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options
Current Vascular Pharmacology Adherence to Secondary Prophylaxis Among Patients with Acute Rheumatic Fever and Rheumatic Heart Disease
Current Cardiology Reviews Cytochrome P450 2C8 and Drug Metabolism
Current Topics in Medicinal Chemistry Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Current Pharmaceutical Design The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry Recent Patents in Plant Biotechnology: Impact on Global Health
Recent Patents on Biotechnology Insulin Treatment and Weight Gain in Type 2 Diabetes: Is Our Knowledge Complete?
Current Nutrition & Food Science Therapeutic Targets to Raise HDL in Patients at Risk or with Coronary Artery Disease
Current Vascular Pharmacology The Role of Hyphenated Chromatography-Mass Spectrometry Techniques in Exploratory Drug Metabolism and Pharmacokinetics
Current Pharmaceutical Design Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches
Current Vascular Pharmacology Combination of Fenofibrate with Non-Statin Drug Regimens
Current Pharmaceutical Design Resveratrol as a Supplemental Therapeutic in Cardiovascular and Metabolic Syndromes: A Critical Review
Current Nutrition & Food Science Prevention of Endothelial Dysfunction and Cardiovascular Disease by n-3 Fatty Acids-Inhibiting Action on Oxidative Stress and Inflammation
Current Pharmaceutical Design Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets